# A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

> **NCT07636785** · PHASE1,PHASE2 · RECRUITING · sponsor: **VM Discovery, Inc.** · enrollment: 111 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Metastatic Uveal Melanoma
- Renal Cell Carcinoma (RCC)
- Nonsmall Cell Lung Cancer
- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** VMD-102

## Key facts

- **NCT ID:** NCT07636785
- **Lead sponsor:** VM Discovery, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-16
- **Primary completion:** 2031-05
- **Final completion:** 2031-12
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636785, "A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07636785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*